IL2RA and neoplasm: Our study provides a systematic comparison between CD25-biased and CD25-blocking IL-2cx in the context of ICI therapy, demonstrating that CD25-biased IL-2cx display superior therapeutic features, including lower systemic toxicity, more selective activation of tumor-specific T cells, and more robust antitumor activity.